Clinical Benefit Of Hepatic Progression-Free Survival Confronts ODAC

A REMS may not be sufficient to address serious toxicity questions about Delcath Systems’ Melblez kit for resectable ocular melanoma that is metastatic to the liver, FDA says in briefing materials for the May 2 advisory committee review of the combination product.